Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verinurad plus allopurinol vs allopurinol vs placebo in chronic kidney disease with hyperuricaemia (Phase 2b)
2018-004079-11Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and hyperuricemia comparing Verinurad plus allopurinol, Allopurinol alone and Placebo (3 arms). Primary endpoint: Change from baseline in UACR at 6 months. Started May 2019; status: completed.
02
Drugs
verinuradallopurinol
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on 2018-004079-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004079-11.